Spruce Biosciences, Inc.
SPRB
$60.95
$0.891.48%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 697.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 697.00K |
| Cost of Revenue | -1.80M | 5.01M | -430.00K | 10.84M | 21.46M |
| Gross Profit | 1.80M | -5.01M | 430.00K | -10.84M | -20.76M |
| SG&A Expenses | 5.00M | 3.22M | 3.12M | 3.66M | 3.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.20M | 8.23M | 2.69M | 14.49M | 24.77M |
| Operating Income | -3.20M | -8.23M | -2.69M | -14.49M | -24.07M |
| Income Before Tax | -14.65M | -8.21M | -2.07M | -14.04M | -23.56M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.65M | -8.21M | -2.07M | -14.04M | -23.56M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.65M | -8.21M | -2.07M | -14.04M | -23.56M |
| EBIT | -3.20M | -8.23M | -2.69M | -14.49M | -24.07M |
| EBITDA | -3.20M | -8.23M | -2.69M | -14.49M | -24.07M |
| EPS Basic | -11.29 | -14.58 | -3.50 | -23.96 | -42.58 |
| Normalized Basic EPS | -3.25 | -9.12 | -2.19 | -14.98 | -26.62 |
| EPS Diluted | -11.29 | -14.58 | -3.50 | -23.96 | -42.58 |
| Normalized Diluted EPS | -3.25 | -9.12 | -2.19 | -14.98 | -26.62 |
| Average Basic Shares Outstanding | 1.30M | 563.10K | 591.10K | 585.90K | 553.20K |
| Average Diluted Shares Outstanding | 1.30M | 563.10K | 591.10K | 585.90K | 553.20K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |